KGK Synergize Receives Multi-Site ISO 9001:2000 Certification
KGK Synergize Inc. (KGK) today announced the achievement of registration of its quality management system, ISO 9001:2000 (#CA05/3474), an international standard published by the International Organization for Standardization (ISO).
London, Ont. -- June 1, 2005 - KGK Synergize Inc. (KGK) today announced the achievement of registration of its quality management system, ISO 9001:2000 (#CA05/3474), an international standard published by the International Organization for Standardization (ISO). The accredited registrar, SGS Systems & Services Certification Canada Inc., confirmed KGK's compliance through a formal audit process. The scope of registration is as follows: "The provision of laboratory testing, analytical services, pre-clinical trials and the establishment of protocols and methods for food products, nature, and the nutraceutical and pharmaceutical product industries in accordance with standard good laboratory practices".
"This important accreditation indicates the on-going dedication of our employees to continuously measure and improve the various processes at KGK, in an effort to present our clients with the best possible customer service available at a research organization", states Robert A. Guthrie, V.P., Contract Research Services Division. "KGK is dedicated to reacting to the needs of our consumers and ISO will enable us to monitor, track and record those needs accordingly".
KGK Synergize provides contract research services in the areas of nutraceutical research, analytical chemistry, immunology, toxicology, autoimmune diseases, etc. and clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
